ExploreWatchlistsPricing
  1. JP-listed companies
  2. Oncolys BioPharma Inc.
  3. Financials
  4. Pretax margin (%)

Oncolys BioPharma Inc. (4588)

Market cap
¥73.3B
P/E ratio
Develops viral therapies for cancer treatment and severe infections, with lead candidate OBP-301 targeting solid tumors like esophageal cancer.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Dec 31, 2025-7,185.7+35.53%
Dec 31, 2024-5,301.8+74.63%
Dec 31, 2023-3,036+2448.27%
Dec 31, 2022-119.1-49.00%
Dec 31, 2021-233.6-57.42%
Dec 31, 2020-548.6+1226.59%
Dec 31, 2019-41.4-94.33%
Dec 31, 2018-729.8+53.82%
Dec 31, 2017-474.5-2.11%
Dec 31, 2016-484.7-31.21%
Dec 31, 2015-704.6-72.05%
Dec 31, 2014-2,521.4-95.24%
Dec 31, 2013-52,991.7+212678.74%
Dec 31, 2012-24.9+695.81%
Dec 31, 2011-3.1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat